Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, and autoimmune and infectious disease therapies in the People's Republic of China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor, which is in Phase III clinical trial for the treatment of ovarian, lung, and breast cancers; ZL-2401, an antibiotic that is in Phase III clinical trial to treat ABSSSI, CABP, and UTI; FPA144, a humanized monoclonal antibody, which is in Phase I/III clinical trial to treat gastric and gastroesophageal cancer; ETX2514, a novel ß-lactamase inhibitor that is in Phase II cUTI trial for the treatment of acinetobacter baumannii; and ZL-2301, which is in Phase III clinical trial to treat HCC.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone86-21-6163-2588
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$130,000.00
Profitability
Miscellaneous
Employees309
Next Earnings DateN/A
OptionableOptionable
Zai Lab (NASDAQ:ZLAB) Frequently Asked Questions
What is Zai Lab's stock symbol?
Zai Lab trades on the NASDAQ under the ticker symbol "ZLAB."
What price target have analysts set for ZLAB?
5 brokerages have issued 1-year price targets for Zai Lab's stock. Their predictions range from $34.70 to $47.00. On average, they expect Zai Lab's share price to reach $40.31 in the next year. This suggests a possible upside of 7.1% from the stock's current price. View Analyst Price Targets for Zai Lab.
What is the consensus analysts' recommendation for Zai Lab?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zai Lab.
Has Zai Lab been receiving favorable news coverage?
News stories about ZLAB stock have trended positive this week, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Zai Lab earned a news sentiment score of 2.5 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the stock's share price in the next several days. View News Stories for Zai Lab.
Who are some of Zai Lab's key competitors?
Some companies that are related to Zai Lab include Catalent (CTLT), Teva Pharmaceutical Industries (TEVA), Jazz Pharmaceuticals (JAZZ), Bausch Health Companies (BHC), Sarepta Therapeutics (SRPT), Beigene (BGNE), Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), Amarin (AMRN), Horizon Therapeutics (HZNP), Ascendis Pharma A/S (ASND), GW Pharmaceuticals PLC- (GWPH), ACADIA Pharmaceuticals (ACAD), Blueprint Medicines (BPMC) and FibroGen (FGEN).
What other stocks do shareholders of Zai Lab own?
Who are Zai Lab's key executives?
Zai Lab's management team includes the folowing people:
- Dr. Ying Du, Founder, Chairman & CEO (Age 53)
- Mr. Tao Fu, Pres, COO & Director (Age 47)
- Mr. Ki Chul Cho, Chief Financial Officer (Age 41)
- Dr. Ning Xu, Exec. VP and Head of Clinical & Regulatory Affairs (Age 54)
- Dr. Qi Liu, Chief Medical Officer of Oncology (Age 54)
When did Zai Lab IPO?
(ZLAB) raised $100 million in an initial public offering on Wednesday, September 20th 2017. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners served as the underwriters for the IPO.
Who are Zai Lab's major shareholders?
Zai Lab's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Segantii Capital Management Ltd (5.66%), Bamco Inc. NY (3.79%), Baillie Gifford & Co. (3.59%), Orbimed Advisors LLC (2.01%), Vanguard Group Inc. (1.96%) and BlackRock Inc. (1.58%).
Which institutional investors are selling Zai Lab stock?
ZLAB stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Cormorant Asset Management LP, WealthPLAN Partners LLC, Platinum Investment Management Ltd., Matthews International Capital Management LLC, Bank of Montreal Can and Invesco Ltd..
Which institutional investors are buying Zai Lab stock?
ZLAB stock was bought by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Segantii Capital Management Ltd, Tree Line Advisors Hong Kong Ltd., Indus Capital Partners LLC, Wells Fargo & Company MN, Jennison Associates LLC, Jennison Associates LLC and BlackRock Inc..
How do I buy shares of Zai Lab?
Shares of ZLAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Zai Lab's stock price today?
One share of ZLAB stock can currently be purchased for approximately $37.65.
How big of a company is Zai Lab?
Zai Lab has a market capitalization of $2.19 billion and generates $130,000.00 in revenue each year. The company earns $-139,070,000.00 in net income (profit) each year or ($2.64) on an earnings per share basis. Zai Lab employs 309 workers across the globe.View Additional Information About Zai Lab.
What is Zai Lab's official website?
How can I contact Zai Lab?
Zai Lab's mailing address is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. The company can be reached via phone at 86-21-6163-2588 or via email at [email protected]
MarketBeat Community Rating for Zai Lab (NASDAQ ZLAB)
MarketBeat's community ratings are surveys of what our community members think about Zai Lab and other stocks. Vote "Outperform" if you believe ZLAB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZLAB will underperform the S&P 500 over the long term. You may vote once every thirty days.
